News

Evonik and Bioamber team up
Enlarge image

BusinessGermany

Evonik and Bioamber team up

25.07.2012 - Evonik Industries and BioAmber join forces on catalysts for sustainable chemicals made from bio-based succinic acid.

Under the terms of the agreement, Evonik and Bioamber will jointly develop and manufacture catalysts for making BDO (1,4- butanediol), THF (tetrahydrofurane) and GBL (gamma - butyrolactone) from bio-based succinic acid. BDO, THF and GBL are large volume industrial chemicals used in a wide range of applications including polymers, paints, adhesives and solvents. The global market for these products, currently made from petrochemicals, is $4bn.

The two companies are well known to each other. Back in 2010, they started a joint development programme for a new generation of BDO catalysts. "Through our collaboration with Evonik, we have secured the expertise and capabilities we need to rapidly bring competitive BDO and THF technology to market," said Jean-Francois Huc, BioAmber CEO. "We are fortunate to have a partner of Evonik’s calibre who can both optimise and manufacture our immediate catalyst needs and also develop with us a new generation of catalysts," Huc added. Bioamber operates the world’s only dedicated production plant for bio-succinic acid in Pomacle, France with a 350,000 litre commercial scale fermenter. The US-based company is pouring more money into building new plants around the globe. Together with Mitsui & Co., it has broken ground in Sarnia, Canada on a 17,000 metric ton bio-succinic acid plant that will be operational in late 2013, with plans to expand capacity to 34,000 metric tons of succinic acid, and a 23,000 metric tons BDO plant in late 2014.

In order to fuel 1st growth, Bioamber has completed its Series C round of financing with net proceeds of $30m. The financing was closed in two tranches; a first tranche of $20m on November last year with existing investors Naxos Capital, Sofinnova Partners, Mitsui & Co. Ltd. and the Cliffton Group. A second tranche of $10m followed this February with specialty chemicals company Lanxess. All of BioAmber’s Series B investors participated in the Series C financing.

http://www.european-biotechnology-news.com/news/news/2012-03/evonik-and-bioamber-team-up.html

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX2.40 EUR6.67%
  • SANTHERA100.10 CHF1.78%
  • ACTELION112.70 CHF1.35%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • VITA 343.70 EUR-5.85%
  • EVOTEC3.68 EUR-1.60%

TOP

  • SANTHERA100.10 CHF67.1%
  • BB BIOTECH142.65 EUR10.2%
  • MAGFORCE6.80 EUR6.1%

FLOP

  • MOLOGEN7.31 EUR-14.0%
  • THERAMETRICS0.07 CHF-12.5%
  • VITA 343.70 EUR-11.1%

TOP

  • SANTHERA100.10 CHF4388.8%
  • CO.DON2.51 EUR213.7%
  • PAION2.43 EUR173.0%

FLOP

  • CYTOS0.25 CHF-93.7%
  • MEDIGENE4.53 EUR-67.5%
  • THERAMETRICS0.07 CHF-53.3%

No liability assumed, Date: 31.08.2014